Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (9790)	5/5/1999 12:01:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Don't think so because they have hired two firms to aggressively seek out partners. Difficult to believe they would do this and then when potential deal seekers are found, stall them off. Also, with all the published research on BPI it would seem a partner with interest in join exploration of specific potential in another area could be found even without a conclusion of the meningo trial. But anything is possible and it is obvious that having the trial over would seem to place XOMA in a better negotiating position. While I do not know, it is possible that XOMA could disclose to prospective partners total deaths to date and the "requirement"